Aptose Biosciences Revenue
Biotechnology Research • 
San Diego, California, United States • 21-50 Employees
Aptose Biosciences revenue & valuation
| Annual revenue | $104,000 |
| Revenue per employee | $4,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $332,800 |
| Total funding | $69,500,000 |
Key Contacts at Aptose Biosciences
William Rice
Chairman, President And Chief Executive Officer
Zoey Liu-Imanuel Phd
Director Of Regulatory Affairs
Janet Clennett
Director Of Finance
Elvia Kasitz
Senior Director Human Resources
Company overview
| Headquarters | 12770 High Bluff Drive, Suite 120, San Diego, California 92130, US |
| Phone number | +18589262730 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Hematology, Oncology, Acute Myeloid Leukemia, Drug Development & Discovery, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Non Hodgkin'S Lymphoma |
| Founded | 2014 |
| Employees | 21-50 |
| Socials |
Aptose Biosciences Email Formats
Aptose Biosciences uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@aptose.com), used 72.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@aptose.com | 72.7% |
{first name}{last name} | johndoe@aptose.com | 27.3% |
About Aptose Biosciences
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies. CG-806, our oral mutation-agnostic FLT3/BTK inhibitor, is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments. CG-806 is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies. APTO-253, our first-in-class MYC Inhibitor, is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Aptose Biosciences has 14 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Aptose Biosciences's funding history, including investment rounds, total capital raised, and key backers.
Funding Insights
$69,500,000
Total funding amount
$11,900,000
Most recent funding amount
8
Number of funding rounds
Aptose Biosciences Tech Stack
Discover the technologies and tools that power Aptose Biosciences's digital infrastructure, from frameworks to analytics platforms.
Web servers
Security
Font scripts
JavaScript libraries
Tag managers
Hosting
Cookie compliance
JavaScript libraries
JavaScript libraries
JavaScript libraries
Miscellaneous
JavaScript libraries
Kuwait
EgyptFrequently asked questions
4.8
40,000 users
